Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation

Atrial FibrillationThrombosis and Stroke

Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation

Int J Cardiol.

Andersson NW, Svanström H, Lund M, Pasternak B, Melbye M

doi: 10.1016/j.ijcard.2018.03.047.

Atrial FibrillationThrombosis and Stroke

Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients

Thromb Haemost.

Li X, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GY

doi: 10.1160/

Atrial FibrillationMyocardial InfarctionThrombosis and Stroke

Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients

J Am Heart Assoc.

Lai CL, Chen HM, Liao MT, Lin TT, Chan KA

doi: 10.1161/JAHA.116.005362.

Atrial Fibrillation

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.

BMJ.

Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB

doi: 10.1136/bmj.j510.

Atrial FibrillationHeart Failure

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure

ESC Heart Fail.

Martinez BK, Bunz TJ, Eriksson D, Meinecke AK, Sood NA, Coleman CI

doi: 10.1002/ehf2.12365.

Atrial FibrillationThrombosis and Stroke

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.

Chest.

Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND

doi: 10.1016/j.chest.2016.07.013.

Atrial Fibrillation

Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease

Am Heart J.

Weir MR, Ashton V, Moore KT, Shrivastava S, Peterson ED, Ammann EM

doi: 10.1016/j.ahj.2020.01.010.

Atrial Fibrillation

Efficacy and Safety of Apixaban versus Warfarin in Patients with Atrial Fibrillation and Extremes in Body Weight: Insights from the ARISTOTLE Trial

Circulation.

Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, Atar D, Hijazi Z, Bahit MC, Al-Khatib SM, Lopez-Sendon JL, Wallentin L, Granger CB, Lopes RD

doi: 10.1161/CIRCULATIONAHA.

Atrial FibrillationHeart, Artery and Coronary DiseasesThrombosis and Stroke

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.

J Am Heart Assoc.

Hu PT, Lopes RD, Stevens SR, Wallentin L, Thomas L, Alexander JH, Hanna M, Lewis BS, Verheugt FW, Granger CB, Jones WS

doi: 10.1161/JAHA.116.004699.

Related content

Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation

Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients

Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.

Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease

Efficacy and Safety of Apixaban versus Warfarin in Patients with Atrial Fibrillation and Extremes in Body Weight: Insights from the ARISTOTLE Trial

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.